Adaptive Biotechnologies products
Drug Discovery
Adaptive - Drug Discovery T-Cell Therapy for Cellular Therapy
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines.
TruTCR is summarized in the figure below.
Biotechnologies - Vaccine
Our TCR-antigen discovery capabilities may inform the design and development of next-generation vaccines. Adaptive has validated hundreds of immunogenic antigens that can be selected to design differentiated vaccines. Our platform is also used to detect and track vaccine-induced antigen-specific T cell responses that correlate with efficacy and safety. Our antigen specificity approach may be used to identify and inform the selection of the most immunogenic antigens to use in the development of either an “off-the-shelf” or a personalized vaccine.
Biotechnologies - Therapeutic Neutralizing Antibodies for SARS-CoV-2
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.